BioNTech SE — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
EribulinThis is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatments the participants actually receive. Participants will receive either the trial drug with chemotherapy or placebo (which looks like the trial drug but does not have any drug in it) with chemotherapy.	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, …	À vérifier
Nab-paclitaxel/PaclitaxelThis is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatments the participants actually receive. Participants will receive either the trial drug with chemotherapy or placebo (which looks like the trial drug but does not have any drug in it) with chemotherapy.	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, …	À vérifier
PumitamigThe purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, …	À vérifier
PumitamigThe purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)	Cancer	Phase 1/2	À vérifier	United States, Argentina, Australia, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Ireland, Italy, Japan, Mexico, Romania, South Korea, Spain, Switzerland, United Kingdom	À vérifier
PumitamigThe purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)	Cancer	Phase 3	À vérifier	United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, Georgia, Germany, Italy, Japan, Mexico, Netherlands, Poland, Singapore, South Korea, Spain, United Kingdom	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Pumitamig	Cancer	Phase 3	NCT07173751	ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer	RECRUITING
Pumitamig	Cancer	Phase 1/2	NCT07293351	A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.